The stock of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) is a huge mover today! About 446,720 shares traded hands. Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) has risen 246.81% since April 14, 2016 and is uptrending. It has outperformed by 242.12% the S&P500.
The move comes after 6 months positive chart setup for the $327.20 million company. It was reported on Nov, 16 by Barchart.com. We have $19.92 PT which if reached, will make NASDAQ:CRBP worth $487.53 million more.
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Ratings Coverage
Out of 4 analysts covering Corbus Pharma (NASDAQ:CRBP), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Corbus Pharma has been the topic of 4 analyst reports since September 8, 2015 according to StockzIntelligence Inc. The stock of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) has “Buy” rating given on Monday, March 7 by Aegis Capital. JMP Securities initiated Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) on Tuesday, September 8 with “Mkt Outperform” rating. Noble Financial maintained the stock with “Buy” rating in Friday, November 11 report. As per Wednesday, October 5, the company rating was initiated by Cantor Fitzgerald.
According to Zacks Investment Research, “Corbus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics to treat life threatening (orphan) inflammatory-fibrotic diseases. The Company’s lead product is Resunab (TM), an oral anti-inflammatory drug that has completed Phase I clinical trials for the treatment of cystic fibrosis and scleroderma. Corbus Pharmaceuticals Holdings, Inc. is based in Norwood, Massachusetts.”
More notable recent Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) news were published by: Fool.com which released: “Why Corbus Pharmaceuticals Holdings Inc. Skyrocketed Higher Today” on November 14, 2016, also Seekingalpha.com with their article: “Corbus Pharmaceuticals: Past And Present” published on November 16, 2016, Fool.com published: “Why Corbus Pharmaceuticals Holdings Inc Jumped Higher Today” on October 19, 2016. More interesting news about Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) were released by: Fool.com and their article: “Why Corbus Pharmaceuticals Holdings Inc Shares Skyrocketed Today” published on October 05, 2016 as well as Marketwatch.com‘s news article titled: “Corbus Pharmaceuticals stock more than doubles after positive drug trial results” with publication date: November 14, 2016.
CRBP Company Profile
Corbus Pharmaceuticals Holdings, Inc., incorporated on December 18, 2013, is a clinical-stage pharmaceutical company. The Firm is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases. The Company’s product, Resunab, is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Resunab is being evaluated in approximately three separate Phase II studies for the treatment of cystic fibrosis (CF), systemic sclerosis and skin-predominant dermatomyositis. The United States Food and Drug Administration (the FDA) has granted Resunab Orphan Drug Designation, as well as Fast Track Status, for both cystic fibrosis and systemic sclerosis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.